Abattis engages British Columbia Institute of Technology to study growth rates and compounds in spinach
VANCOUVER, Feb. 4, 2013 /PRNewswire/ – Abattis Bioceuticals Corp. (the
“Company” or “Abattis”) (OTC PINK: ATTBF) (CNSX: FLU), announces the
engagement of BCIT to study the growth rates and novel compounds
present in baby spinach.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company,
stated, “We are pleased to start on this project as it will
substantiate the Vertical Automated Grow System (VAGS) acquired from
Vertical Designs Ltd. and serve as a benchmark for growing, processing
and the proprietary extraction of botanicals under strict Standard
Operating Protocols to achieve pharmaceutical grade products.” Mr.
Withrow went on to state, “This is our first step toward producing
bio-pharma grade botanicals that are standardized to targeted
Dr. Paula N. Brown, Director of Applied Research for BCIT’s Natural
Health & Food Products Research Group, stated, “The proposed research
project focuses on the controlled and sustainable production of plants
to meet the demand for a traceable and consistent supply of botanical
materials for development of biopharmaceuticals.” Under the direction
of Dr. Brown, BCIT has worked with the natural health product sector
for over a decade conducting applied research, including product
development, establishment of quality standards and regulatory
compliance. By providing fundamental investigations on product quality,
safety and efficacy, BCIT supports industry through the entire
continuum, from grower to manufacturer, ensuring product integrity is
maintained. “We are excited to be working with this group”, continued
Dr. Brown, “as the expertise and technology afforded by the combination
of the VAGS and Abattis could serve as a model for development of
value-added products and potential therapeutics from a wide variety of
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and bio-similar
compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and
Animal Nutrition markets. The company also has a deep pipeline of
proprietary products ready for sale in high growth areas of Functional
Foods and Supplements business. For more information, visit the
Company’s website at www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
Neither the CNSX Exchange nor its regulations services accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.